Sample Submission Guidelines
What This Service Solves
A generic multi-omics integration project asks how molecular layers relate to one another. A drug-response project adds a harder requirement: every molecular observation must be interpreted in relation to a treatment, dose, time point, response endpoint, or resistance state.
From Response Phenotype to Testable Biology
When projects need broader harmonization before treatment-specific modeling, our multi-omics data integration workflow can provide the upstream integration framework.
- Baseline response signatures: Identify molecular features associated with quantitative sensitivity or prespecified experimental response groups.
- Treatment-induced MOA evidence: Link dose- and time-aware molecular changes to pathways, regulators, and target-network biology.
- Resistance mechanisms: Compare sensitive and resistant states to prioritize escape pathways and alternative vulnerabilities.
Mechanistic interpretation remains hypothesis-driven until supported by orthogonal experimental validation.
Supported Study Designs and Data Inputs
We support studies that begin with one omics layer plus a response phenotype or extend across several matched molecular layers. Input can come from different platforms when treatment metadata and sample identifiers remain traceable.
| Data Layer | Accepted Input | Drug-Response Contribution |
|---|---|---|
| Genomics | FASTQ, BAM, annotated VCF, mutation or copy-number matrix | Baseline genotype, pathway lesions, resistance-associated variants |
| Transcriptomics | FASTQ, BAM, count matrix, normalized expression matrix | Baseline response signatures, treatment-induced programs, pathway activity |
| Epigenomics | Methylation calls, ATAC-seq peaks, ChIP-seq signal or processed matrices | Regulatory state and treatment-associated regulatory shifts |
| Proteomics / PTM | LC-MS/MS raw data or protein/PTM quantification matrices | Functional pathway changes, signaling responses, target-network evidence |
| Metabolomics / Lipidomics | Raw MS files, peak tables, annotated metabolite matrices | Metabolic response, pathway remodeling, resistance-associated states |
| Single-Cell Data | FASTQ, count matrices, Seurat/AnnData objects | Cell-state-specific response and resistant subpopulations |
| Response Phenotype | IC50, AUC, DSS, viability, growth inhibition, assay score, research response class | Defines the supervised endpoint or association target |
For upstream processing, projects may use genomic data analysis, transcriptomic data analysis, or epigenomics data analysis before treatment-linked integration.
Project Entry Options
Two ways to start a drug-response multi-omics project
Data-to-Insight
- You provide existing response measurements and molecular data.
- We perform QC, harmonization, endpoint review, response modeling, multi-omics integration, and mechanism interpretation.
- Best for teams with data already generated internally or through prior vendors.
Sample-to-Insight
- You provide biological samples and the experimental design.
- Qualified partner platforms generate the requested omics data before analysis.
- Best for programs needing coordinated upstream data generation and downstream interpretation.
Either entry mode can support baseline-only response studies, paired treatment studies, longitudinal designs, acquired-resistance models, or mixed private/public evidence projects.
AI-Assisted Drug Response and MOA Workflow
The workflow is built around the treatment question rather than a fixed algorithm. AI and machine learning enter only after the response endpoint, data provenance, and sample relationships are defined.
Step 1: Study Framing & Endpoint Definition
Confirm compound, treatment arms, dose and time structure, model system, response endpoint, omics layers, covariates, and the intended research claim.
Step 2: Data / Sample Reception & QC
Audit sample IDs, response tables, missingness, replicate structure, batch variables, and platform-specific QC; coordinate partner data generation for sample-based projects.
Step 3: Layer-Specific Perturbation Analysis
Process each omics layer independently first and evaluate normalization, differential signals, dose/time effects, and batch structure before cross-layer fusion.
Step 4: Response-Linked Integration & Modeling
Link molecular features to quantitative or categorical response endpoints using regularized models, tree-based ensembles, latent factors, or network methods as appropriate.
Step 5: MOA & Resistance Interpretation
Map prioritized features to pathways, regulators, protein interactions, metabolite relationships, and known target biology while separating baseline predictors from downstream treatment effects.
Step 6: Validation Prioritization & Delivery
Stress-test signatures, summarize uncertainty, compare with compatible independent evidence, and rank orthogonal validation experiments, biomarkers, pathways, or combination hypotheses.
Choosing the Right Analysis Strategy
A response-prediction model is not automatically the best way to answer an MOA question. We select the strategy according to endpoint quality, sample size, temporal design, and validation resources.
| Strategy | Best Research Question | Primary Output | Key Limitation |
|---|---|---|---|
| Baseline Response Association | What differs before treatment between high- and low-response models? | Stable features, response signature, subgroup patterns | Association does not establish drug mechanism |
| Supervised Response Modeling | Can molecular profiles predict an experimental response endpoint? | Cross-validated model, feature importance, performance summary | High-dimensional small cohorts can overfit |
| Paired Perturbation / MOA | What changes after compound exposure? | Differential pathways, regulators, cross-omics mechanism map | Post-treatment changes may be secondary effects |
| Resistance-Focused Integration | What distinguishes sensitive, tolerant, or resistant states? | Escape pathways, resistance modules, candidate vulnerabilities | Resistance can be heterogeneous and model-specific |
| Hybrid Private + Public Evidence | Does the internal signal recur in external pharmacogenomic resources? | Independent context, external support, boundary conditions | Assay, dose, platform, and biology may differ |
For cell-state-specific response, single-cell RNA-seq analysis can be incorporated when bulk averages would hide resistant or treatment-responsive subpopulations.
Validation and Research Safeguards
Drug-response modeling is vulnerable to hidden dependence and leakage. Validation design is therefore part of the biological question, not a final plotting step.
- Endpoint definition before modeling: Thresholds, transformations, or quantitative outcomes are specified before feature selection.
- Leakage-controlled preprocessing: Scaling, imputation, feature selection, and tuning remain within training data.
- Biologically meaningful evaluation: Splits can separate samples, model systems, compounds, batches, or cohorts depending on the question.
- Baseline comparison: Complex models are compared with simpler statistical or regularized baselines.
- Batch and confounder review: Treatment, dose, time, tissue, genotype, culture system, and assay plate effects are assessed.
- Cross-omics convergence: Mechanism hypotheses rank higher when independent molecular layers support the same pathway in compatible directions.
- Causal restraint: Feature importance, correlation, and enrichment support prioritization; causal MOA requires orthogonal validation.
Deliverables
- Per-layer QC, normalization, batch, missingness, and endpoint review
- Harmonized sample, treatment, dose, time, and response metadata table
- Differential treatment-response results for each omics layer
- Multi-omics response-associated feature matrix and ranked candidate signature
- Cross-validated classification or regression outputs when justified
- Feature-attribution summaries, pathway activity results, and regulator/network maps
- Responder or resistance subgroup assignments when supported by the design
- MOA and resistance evidence matrix connecting features, pathways, and treatment context
- Public-dataset contextualization or external validation when appropriate
- Reproducible code, environment/version information, analysis-ready tables, and methods-ready documentation
Sample and Data Requirements
Requirements depend on model complexity, response distribution, omics dimensionality, replicate structure, and validation goals. We assess feasibility against the actual design rather than impose a universal numeric minimum.
| Input Category | Accepted Input | Required Metadata | How It Is Used |
|---|---|---|---|
| Compound / Treatment | Compound identity or internal ID; single agent or defined combination | Dose, exposure time, vehicle/control, treatment arm | Establishes perturbation structure |
| Response Phenotype | IC50, AUC, DSS, viability, growth inhibition, assay score, research response class | Assay method, normalization, replicate structure, response definition | Defines supervised or association endpoint |
| Omics Data | Raw files or processed matrices from supported layers | Sample ID, platform, batch/run, preprocessing history | Provides molecular features and perturbation readouts |
| Sample Relationships | Baseline, treated, resistant, longitudinal, or matched pairs | Pairing key, time point, model system, biological replicate | Determines paired, longitudinal, or subgroup analyses |
| Covariates | Model-system attributes, genotype, tissue, experimental conditions | Variable definitions and missing-value coding | Controls confounding and supports stratified interpretation |
| External / Public Data | Published or public pharmacogenomic datasets | Source, version, mapping key, license/provenance | Adds context or independent validation when compatible |
Study Design Requirements and Limitations
The strongest projects define a response endpoint that is biologically meaningful for the model system and collect molecular measurements under a design that allows treatment effects to be separated from time, batch, and baseline differences. Biological replication, balanced allocation, consistent sample handling, and complete dose/time metadata materially improve interpretability.
- Small cohorts may support exploratory pathway analysis without supporting a stable supervised predictor.
- Severe class imbalance can make accuracy misleading and reduce signature stability.
- Post-treatment-only designs cannot establish baseline predictive biomarkers without additional data.
- Response labels derived from the same molecular features used for prediction can create circularity.
- Cross-platform public datasets may add context without being directly poolable with proprietary experiments.
- Reproducible cross-omics association does not by itself prove a compound's direct molecular target.
References
- Cai Z, Apolinário S, Baião AR, et al. Synthetic augmentation of cancer cell line multi-omic datasets using unsupervised deep learning. Nature Communications. 2024;15:10390. Cai et al., 2024
- Walsh I, Fishman D, Garcia-Gasulla D, et al. DOME: recommendations for supervised machine learning validation in biology. Nature Methods. 2021;18:1122–1127. Walsh et al., 2021
- Rashid M, Selvarajoo K. Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data. Briefings in Bioinformatics. 2024;25(4):bbae300. Rashid and Selvarajoo, 2024
- Sharifi-Noghabi H, Zolotareva O, Collins CC, Ester M. MOLI: multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics. 2019;35(14):i501–i509. Sharifi-Noghabi et al., 2019
Demo Results
Illustrative outputs show how treatment phenotype, molecular features, and pathway interpretation can be traced through the analysis. Demo figures represent output types rather than guaranteed performance benchmarks.
Response-Stratification Heatmap With Molecular Feature Modules
Cross-Omics MOA and Resistance Pathway Network
Interpretable Response Feature Ranking and Pathway Attribution
AI-Assisted Multi-Omics Drug Response Analysis FAQs
1. Do I need both pre-treatment and post-treatment omics?
No. Baseline omics matched to a response phenotype can support response-association or prediction projects, while paired pre/post-treatment data are more informative for pharmacodynamic and MOA questions. If both are available, we separate baseline predictors from treatment-induced changes.
2. Can you analyze IC50, AUC, DSS, viability, or categorical response labels?
Yes, provided the endpoint is well defined and assay metadata are available. Quantitative endpoints can be modeled continuously, while categorical groups require a defensible threshold or prespecified experimental definition.
3. How do you avoid data leakage in drug-response models?
Preprocessing, imputation, feature selection, and tuning are confined to training data. We also review shared compounds, model systems, batches, donors, or derived measurements that could create hidden dependence between training and evaluation sets.
4. Can the analysis distinguish predictive biomarkers from mechanism-of-action evidence?
Yes. Baseline features associated with response are predictive candidates. Treatment-induced pathway changes are pharmacodynamic or mechanistic evidence. A feature can contribute to both, but each interpretation must be supported by the relevant data relationship.
5. Can public drug-response datasets be integrated with our proprietary data?
Yes, when compound, target, model system, feature definitions, and assay context are compatible. Public data are often most useful for external context, replication, model pretraining, or sensitivity analysis rather than direct pooling with a proprietary test set.
6. What if the omics layers are only partially matched?
Partial overlap does not automatically prevent analysis. We define which samples support paired cross-omics inference and which layers should remain separate. Factor models, network integration, or staged evidence synthesis may be more defensible than complete-case concatenation.
AI-Assisted Multi-Omics Drug Response Case Study
Independent Published Example
Synthetic augmentation of cancer cell line multi-omic datasets using unsupervised deep learning
Journal: Nature Communications
Published: 29 November 2024
License: CC BY 4.0
Background
Cai and colleagues developed MOSA, a conditional multi-view variational autoencoder for cancer multi-omics integration. The study assembled genomics, methylomics, transcriptomics, proteomics, metabolomics, drug response, and CRISPR-Cas9 gene essentiality across 1,523 cancer cell lines with at least two data layers available.
Materials & Methods
Multi-Omics Scope
- 7 molecular/phenotypic data types
- 1,523 cancer cell lines
- At least 2 data layers per cell line
Independent Drug-Response Test
- 32,659 IC50 measurements
- 313 unique drugs
- 781 overlapping cancer cell lines
Interpretation
- Independent dataset validation
- SHAP feature attribution
- Drug-specific multi-omics explanations
Results
- The independent drug-response dataset was reconstructed with Pearson's r = 0.87 across 32,659 IC50 measurements.
- The authors also reported robust reconstruction of 107 overlapping drugs in a separate CTD2 dataset.
- Metabolomics, drug response, and copy-number alterations had the highest average feature importance among the omics layers in the shared representation.
- Figure 4 shows SHAP explanations across omics layers and for individual drug-response reconstructions, including features associated with pyrimethamine response.
Conclusion
This independent study demonstrates why multi-omics drug-response analysis should pair predictive or reconstructive performance with transparent feature attribution and independent validation. Model outputs can prioritize mechanism hypotheses, but pathway, network, and experimental evidence remain necessary before assigning causal MOA.
Reference
- Cai Z, Apolinário S, Baião AR, et al. Synthetic augmentation of cancer cell line multi-omic datasets using unsupervised deep learning. Nature Communications. 2024;15:10390. Published article and Figure 4
Related Publications
Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data
Journal: Briefings in Bioinformatics
Year: 2024
MOLI: multi-omics late integration with deep neural networks for drug response prediction
Journal: Bioinformatics
Year: 2019
Explore our broader Multi-Omics Analysis solutions for related integrative research workflows.
For Research Use Only. Not for use in diagnostic or clinical procedures.
